This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Sygnature have acquired Peak Proteins Ltd. Following an extensive partnership between the two companies, this deal will enable seamless integration of proteinproduction and related structure determination projects within Sygnature. The Peak Proteins leadership team will also remain with the business.
5 And for the latter, the development of a technique to temporally track gene expression in CHO cells, which therefore has the potential to lead to the identification of targets to improve recombinant proteinproduction. 2016), 32: 1301-1307 Matasci M, Baldo L, et al. 2007), 103(7): 40–47. Rajendra Y, Peery RB, Barnard GC.
Using the obtained sequencing data, Kao Corporation was able to produce an antibody sample in one week using proteinproduction technology such as enzymes cultivated by our technology. Comment from Fumiharu Muroga, Growth Manager at Real Tech Fund]
“Proteins are an important structural component of living things.
In 2012, an Israeli company called Protalix gained approval for their plant-based enzyme product for Gaucher’s disease. In 2016, a company called Synageva BioPharma (formerly AviGenics) was acquired by Alexion for $8.4B. Tiamat Sciences harvests a variety of proteinproducts in tobacco plants.
” About Elasmogen:
Spun-out from the University of Aberdeen, Scotland in 2016, Elasmogen is developing soloMERs ; fully humanized (or de-immunised) VNAR, as next generation, single chain therapeutics for auto-inflammatory diseases, oncology and intracellular delivery.
Philosophical Transactions of the Royal Society B (2016). Link →A Brief History of De Novo Protein Design: Minimal, Rational, and Computational , by Woolfson D.N. Link The coming of age of de novo protein design , by Huang P-S. Nature (2016). Science (2016). Nature (2016). & Charpentier E.
Philosophical Transactions of the Royal Society B (2016). Link →A Brief History of De Novo Protein Design: Minimal, Rational, and Computational , by Woolfson D.N. Link The coming of age of de novo protein design , by Huang P-S. Nature (2016). Science (2016). Nature (2016). Cell (2016).
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content